Approach to the patients with the hallucinations, in the Parkinson’s disease in the low-income country and environment of restricted medications and stigmas
Objective: Expose the percentage of patients with hallucinations in studying group of Parkinson’s disease patients in Uzbekistan. Background: Uzbekistan has 35 million population, largest in…Minor hallucinations in Parkinson’s disease are associated with increased neurofilament plasma levels and reduced white-matter integrity in the inferior longitudinal fasciculus
Objective: To examine whether patients with Parkinson's disease (PD) and isolated minor hallucinations have increased plasma neurofilament light chain (NfL) levels and/or differences in white…Homer1 polymorphism in patients with Parkinson’s disease and psychosis
Objective: To explore the association of psychosis in Parkinson’s disease with polymorphisms of HOMER1, a gene whose product (Homer1) is responsible for modulating the metabotropic…Increased illusory responses in non-hallucinating, cognitively impaired Lewy body disease patients
Objective: To determine whether non-hallucinating Lewy body disease-spectrum patients report increased illusory responses. Background: Pareidolias are specific illusions of faces and objects perceived in formless…Relationship between RBD and olfactory disorder, clinical symptoms in Parkinson’s disease
Objective: We aimed to assess the association among RBD, olfactory function and clinical symptoms in patients with Parkinson's disease (PD). Background: Rapid eye movement sleep…Visual subnetwork dysfunction in Parkinson’s patients with primary visual hallucinations
Objective: To evaluate impairments in the visual subnetwork in Parkinson’s disease (PD) patients with psychosis using BOLD fMRI Background: Psychosis occurs in 20-70% of patients…Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease
Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…Rivastigmine for visual hallucinations in Parkinson’s disease
Objective: The aim of the study is to investigate whether early rivastigmine treatment of visual hallucinations in patients with Parkinson's disease delays the progression of…The role of dysfunctional attentional processing in isolated minor hallucinations in Parkinson’s disease
Objective: To explore attentional processing deficits in Parkinson's disease (PD) with minor hallucinations using a selective visual attention task. Background: Recent literature points to a…Frequency of neuropsychiatric symptoms in non-demented early and late-onset Parkinson’s disease patients
Objective: To compare the frequency of neuropsychiatric symptoms (NPS) (depression, anxiety, psychotic, irritability, aggression, euphoria, apathy, behavioral disinhibition, repetitive motor behavior (RMB) and eating disorder)…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 11
- Next Page »